A $575M raise at a $10.1B valuation came with a new kind of validation: a spot in a ten-year CMS program built for chronic disease management.
WHOOP built its business on athletes and fitness enthusiasts who wanted to optimize sleep and training. Its most recent move suggests the company sees a much bigger opportunity sitting right next to that one.
A wellness wearable enters a Medicare chronic care model
WHOOP closed a $575M Series G round led by Collaborative Fund in March 2026 at a $10.1B valuation, according to Crunchbase. In the same year, WHOOP was selected to participate in CMS's ACCESS model, a ten-year program launching July 5, 2026, designed to support technology-enabled chronic disease management for Medicare beneficiaries with conditions including diabetes, hypertension, and cardiovascular disease. Doctronic, Headspace, and Noom were also selected for the same program.
This is happening even as WHOOP faces real regulatory friction elsewhere: the FDA issued a warning letter over WHOOP's Blood Pressure Insights feature for unauthorized marketing, then escalated to a consumer safety communication, and WHOOP has publicly refused to disable the feature, according to Sacra's company analysis.
WHOOP members log more than 90 additional minutes of exercise per week, over two extra hours of sleep, and 10% higher heart rate variability than non-members, according to the company, precisely the kind of longitudinal behavior data a chronic disease management program is built to use.
Passive data is the actual asset, not the device
Consumer wearables generate passive biometric data streams without requiring any conscious action from the user, which is exactly what makes them attractive to chronic disease management programs looking for low-cost, always-on monitoring tools. That's a fundamentally different value proposition than the fitness-optimization pitch WHOOP built its consumer business on, and it's why a wellness company can plausibly sit inside a Medicare program alongside AI doctor platforms and behavioral health apps.
The regulatory tension isn't incidental to this story, it's the actual friction point. A device the FDA is actively warning about for one clinical claim is simultaneously being invited into a federal chronic care program for a different one, which says as much about how unsettled the wellness-to-medical boundary currently is as it does about WHOOP specifically.
Whether other wellness wearables follow the same regulatory tightrope
Watch whether Oura, which now offers its own blood-testing strategy to match WHOOP's move toward clinical claims, pursues a similar CMS or FDA pathway, or holds back given WHOOP's current regulatory friction. Also watch how the ACCESS model's 2026-27 performance data treats wearable-sourced engagement data compared to more traditional clinical inputs, since that will signal whether CMS sees passive wearable data as genuinely equivalent evidence or a lower-tier supplement.
